Ishlt ConsensusReport from a consensus conference on primary graft dysfunction after cardiac transplantation
Section snippets
Clinical background
Although survival after cardiac transplantation has been improving for the last 2 decades, whether the incidence and mortality from PGD has followed suit is unclear from the literature.2, 3, 4 This lack of clarity stems not from the amount of research conducted on the topic of PGD but instead from the lack of standardization of diagnostic criteria. Parameters such as requirement of inotropic support, left ventricular (LV) ejection fraction (LVEF), and requirement of cardiac mechanical support
Epidemiology and outcomes: Josef Stehlik
Although ascertainment of the exact incidence of PGD from registry data is not possible, these data provide us with important information about the epidemiology and the clinical characteristics associated with PGD. Data of interest available in the ISHLT Transplant Registry (Registry) include donor, recipient, and transplant event characteristics, early mortality, and the causes of death.2, 4
Examination of early mortality after heart transplant documented in the Registry reveals that 66% of the
PGD Experience in select transplant centers
The consensus conference also consisted of presentations from high-volume transplant centers regarding their experience and their management of PGD. These are summarized in Table 4. These presentations provided a basis for further discussion on treatment of PGD and use of inotropic agents and mechanical circulatory support.
Breakout sessions from the PGD consensus conference
Although specific background presentations took place in the morning of the consensus conference, the afternoon was devoted to breakout discussion sessions. The participants were divided into 3 groups to allow for further discussion and interaction. Each group included a mix of cardiologists, cardiac surgeons, pathologists, and immunologists. Clinical issues regarding recognition, management, and prevention of PGD were discussed similarly amongst participants in the 3 groups. All points of
Summary of the consensus statements on PGD
After the breakout sessions, the reconvened conference focused on reaching consensus on salient topics pertaining to diagnosis and management of PGD. The discussion throughout the day had made it clear that standardization of the definition of PGD was one of the most important requirements of the conference. This would allow easier recognition of the phenomenon and communication between clinicians. It was decided that graft dysfunction be distinguished as primary graft dysfunction (PGD) as
Consensus statements
- 1.
Graft dysfunction is to be classified into PGD or secondary graft dysfunction where there is a discernible cause such as hyperacute rejection, pulmonary hypertension, or known surgical complications (e.g., uncontrolled bleeding; Table 5).
- 2.
The diagnosis of PGD is to be made within 24 hours after completion of the cardiac transplant surgery.
- 3.
PGD is to be categorized into PGD-LV or PGD-RV (Table 6).
- 4.
A severity scale for PGD-LV will include mild, moderate or severe grades based on specified criteria (
Disclosure statement
The authors express their deepest appreciation and gratitude to Christine Sumbi for organizing and planning this conference.
This conference was jointly funded by the ISHLT and the Cedars-Sinai Heart Institute.
Jon Kobashigawa, MD, is scientific medical advisor to TransMedics Inc and Novartis, and discloses research grants and research support from Novartis and XDx Inc. Fardad Esmailian, MD, is a member of steering committee for PROCEED II trial. Jignesh Patel, MD, PhD, discloses research grants
References (70)
- et al.
Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation
J Heart Lung Transplant
(2005) - et al.
The Registry of the International Society for Heart and Lung Transplantation: twenty-eighth adult heart transplant report—2011
J Heart Lung Transplant
(2011) - et al.
Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult heart transplant report—2008
J Heart Lung Transplant
(2008) - et al.
Primary graft failure after heart transplantation: the importance of donor pharmacological management
Transplant Proc
(2010) - et al.
Impact of warm ischemia time on survival after heart transplantation
Transplant Proc
(2012) - et al.
Association between primary graft dysfunction among lung, kidney and heart recipients from the same multiorgan donor
Am J Transplant
(2008) - et al.
RADIAL: a novel primary graft failure risk score in heart transplantation
J Heart Lung Transplant
(2011) - et al.
Management of acute severe perioperative failure of cardiac allografts: a single-centre experience with a review of the literature
Can J Cardiol
(2007) - et al.
A novel method of measuring cardiac preservation injury demonstrates University of Wisconsin solution is associated with less ischemic necrosis than Celsior in early cardiac allograft biopsy specimens
J Heart Lung Transplant
(2012) - et al.
Functional evidence of reversible ischemic injury immediately after the sympathetic storm associated with experimental brain death
J Heart Lung Transplant
(2003)
Desensitization of myocardial beta-adrenergic receptors and deterioration of left ventricular function after brain death
J Thorac Cardiovasc Surg
Activation of proinflammatory genes in somatic organs as a consequence of brain death
Transplant Proc
The effect of ischemic time on survival after heart transplantation varies by donor age: an analysis of the United Network for Organ Sharing database
J ThoracCardiovasc Surg
The use of donor hearts with left ventricular hypertrophy
J Heart Lung Transplant
NHE-1: Still a viable therapeutic target
J Mol Cell Cardiol
Preoperative pulmonary hemodynamics and early mortality after orthotopic cardiac transplantation: the Pittsburgh experience
Am Heart J
Pre-transplant reversible pulmonary hypertension predicts higher risk for mortality after cardiac transplantation
J Heart Lung Transplant
Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery
Ann Thorac Surg
Pre-operative risk factors and clinical outcomes associated with vasoplegia in recipients of orthotopic heart transplantation in the contemporary era
J Heart Lung Transplant
Determinants of early graft failure following cardiac transplantation, a 10-year, multi-institutional, multivariable analysis
J Heart Lung Transplant
Who is the high-risk recipient? Predicting mortality after heart transplant using pretransplant donor and recipient risk factors
Ann Thorac Surg
Extracorporeal membrane oxygenation in primary graft failure after heart transplantation
Ann Thorac Surg
Primary graft failure after heart transplantation: Characteristics in a contemporary cohort and performance of the RADIAL risk score
J Heart Lung Transplant
Serum troponin Ic values in organ donors are related to donor myocardial dysfunction but not to graft dysfunction or rejection in the recipients
Int J Cardiol
Donor cardiac troponin I levels do not predict recipient survival after cardiac transplantation
J Heart Lung Transplant
Elevated donor cardiac troponin T and procalcitonin indicate two independent mechanisms of early graft failure after heart transplantation
Int J Cardiol
Levosimendan: a new therapeutic option in the treatment of primary graft dysfunction after heart transplantation
J Heart Lung Transplant
Levosimendan for primary graft failure after heart transplantation: a 3-year follow-up
Transplant Proc
Extracorporeal membrane oxygenation is superior to right ventricular assist device for acute right ventricular failure after heart transplantation
Ann Thorac Surg
The PROCEED II International Heart Transplant Trial with the Organ Care System Technology (OCS)
J Heart Lung Transplant
Registry of the International Society for Heart and Lung Transplantation: introduction to the 2010 annual reports
J Heart Lung Transplant
Myocardial and endothelial protection for heart transplantation in the new millenium: lessons learned and future directions
J Heart Lung Transplant
Impact of donor spontaneous intracranial hemorrhage on outcome after heart transplantation
Am J Transplant
Usefulness of extracorporeal membrane oxygenation for early cardiac allograft dysfunction
J Heart Lung Transplant
Differences in early postoperative complications in elective and emergency heart transplantation
Transplant Proc
Cited by (479)
Recipient Outcomes With Extended Criteria Donors Using Advanced Heart Preservation: An Analysis of the GUARDIAN-Heart Registry
2024, Journal of Heart and Lung TransplantationDonor Heart Recovery and Preservation Modalities in 2024
2024, JACC: Heart FailureHypothermic oxygenated perfusion (HOPE) safely and effectively extends acceptable donor heart preservation times: Results of the Australian and New Zealand trial
2024, Journal of Heart and Lung TransplantationHLA sensitization is associated with an increased risk of primary graft dysfunction after heart transplantation
2024, Journal of Heart and Lung TransplantationImpact of postoperative hyperlactatemia in orthotopic heart transplantation
2024, Journal of Cardiology